Effect of hypoxia inducible factor stabilizer on hematopoietic function and ferroptosis in hemo-dialysis patients with renal anemia
Objective To investigate the effect of hypoxia inducible factor stabilizer on hema-topoietic function and iron metabolism in hemodialysis patients with renal anemia.Methods The pro-spective study method was applied,and 90 patients with chronicity kidney disease(CKD)complica-ting renal anemia in our hospital from January 2018 to January 2021 were enrolled,and equally divided into group A and group B according to random number table method,with 45 cases in each group.Group A received roxadustat,while group B received recombinant human erythropoietin injection.A-nemia,iron metabolism-related indexes,lipid metabolism-related indexes,serum inflammatory indexes and drug complications were observed at baseline,2,4,8 and 12 weeks after treatment,and all pa-tients completed a half year follow-up.Then the incidence of adverse cardiovascular events was statisti-cally analyzed.Results Within group A,levels of hemoglobin(Hb),red blood cell(RBC),hema-tocrit(HCT)and serum ferritin(SF)in group A were significantly increased(all P＜0.05),mean-time,the levels of triglyceride(TG),total cholesterol(TC),C-reactive protein(CRP)and β2-mi-croglobulin(β2-MG)were significantly decreased after treatment(all P＜0.05).At each time point after treatment,Hb and SF levels in group B were significantly increased(all P＜0.05),while RBC,HCT,TG,TC,CRP and β2-MG levels showed no significant changes(all P＞0.05).After treat-ment,the levels of Hb,RBC,HCT and SF in group A were significantly higher than those in group B at each time point(all P＜0.05),and the levels of TG,TC,CRP and β2-MG in group A were signif-icantly lower than those in group B at the same time point(all P＜0.05).Serum GPX4 and PTGS2 mRNA levels in group A after treatment were significantly decreased at all time points compared with before treatment(all P＜0.05),while there was no statistical significance in GPX4 and PTGS2 mR-NA levels in group B at all time points compared with before treatment(all P＞0.05).The mRNA levels of GPX4 and PTGS2 in group A were significantly lower than those in group B at all time points after treatment(all P＜0.05).Conclusions Roxadustat in the treatment of renal anemia can effec-tively and safely ameliorate the iron metabolism,lipid metabolism disorder and inhibit the body inflam-matory response,which is of great clinical value.
万方数据
维普
